摘要
目的:探讨膀胱热灌注化疗和卡介苗(BCG)膀胱灌注预防高危非肌层浸润性膀胱癌患者术后复发的安全性和有效性。方法:回顾性分析2019年8月—2021年8月在新乡医学院第一附属医院行经尿道膀胱肿瘤电切术,且术后行吉西他滨膀胱热灌注化疗(HIVEC-GEM)或BCG膀胱灌注的高危非肌层浸润性膀胱癌患者资料共74例,其中38例行HIVEC-GEM膀胱灌注(HIVEC-GEM组),36例行BCG膀胱灌注(BCG组),比较两组术后肿瘤复发率和进展率以及不良反应发生率。结果:两组术后6个月的复发率(5.26%vs.2.78%,χ^(2)=0.002)和进展率(5.26%vs.2.78%,χ^(2)=0.002)、术后12个月的复发率(13.16%vs.8.33%,χ^(2)=0.086)和进展率(10.53%vs.8.33%,χ^(2)=0.006)以及术后24个月的复发率(18.42%vs.13.89%,χ^(2)=0.279)和进展率(13.16%vs.11.11%,χ^(2)=0.007)差异均无统计学意义(均P>0.05),多种不良反应发生率之间的比较也无统计学意义(均P>0.05)。结论:HIVEC-GEM的疗效和安全性与BCG膀胱灌注相当。
Objective:To explore the safety and effectiveness of hyperthermic intravesical chemotherapy(HIVEC)and Bacillus Calmette Guerin(BCG)intravesical chemotherapy in preventing the postoperative recurrence of high-risk non-muscle invasive bladder cancer.Methods:This study retrospectively analyzed the clinical data of patients with high-risk non-muscle invasive bladder cancer who underwent transurethral resection of bladder tumor(TURBT)in the Frist Affiliated Hospital of Xinxiang Medical College from August 2019 to August 2021.These patients received postoperative hyperthermic intravesical chemotherapy with gemcitabine(HIVEC-GEM)or BCG intravesical chemotherapy.A total of 74 patients,with 38 undergoing HIVEC-GEM and 36 undergoing BCG therapy,were divided into the HIVEC-GEM group and the BCG group.The groups were compared based on the recurrence rate and progression rate of the tumor,as well as the incidence of adverse events.Results:The recurrence rates at 6 months(5.26%vs.2.78%,χ^(2)=0.002)and 12 months(13.16%vs.8.33%,χ^(2)=0.086)post-surgery,as well as the progression rates at 6 months(5.26%vs.2.78%,χ^(2)=0.002),12 months(10.53%vs.8.33%,χ^(2)=0.006),and 24 months(13.16%vs.11.11%,χ^(2)=0.086)post-surgery,showed no significant difference between the two groups(all P>0.05).Additionally,there was no statistical significance in the incidence of multiple adverse events(all P>0.05).Conclusion:The efficacy and safety of HIVEC-GEM are comparable to those of BCG therapy.
作者
李泽宇
张冠英
张春锋
宋伟航
何岩
LI Zeyu;ZHANG Guanying;ZHANG Chunfeng;SONG Weihang;HE Yan(Urology Department 2 of the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,China)
出处
《天津医科大学学报》
2024年第4期328-331,370,共5页
Journal of Tianjin Medical University
关键词
膀胱癌
膀胱热灌注化疗
卡介苗
吉西他滨
bladder cancer
hyperthermic intravesical chemotherapy
BCG
gemcitabine
